research Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
Search
for
Sort by
Research
420-450 / 1000+ results research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Tether-induced tenosynovitis: The importance of an intact skin barrier
An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo
3D imaging effectively tracks skin changes in vitiligo treatment.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
research Recovery of resistant alopecia areata treated with tofacitinib: An 8-year-old child's case report
Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
research Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
research An Update on Medical Treatment Options for Hidradenitis Suppurativa
New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
research Frontal Fibrosing Alopecia: A Review
Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research Facial Psoriasis Log-based Area and Severity Index: A valid and reliable severity measurement method detecting improvement of facial psoriasis in clinical practice settings
The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.
research Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database
Certain drugs may cause vitiligo, so patients should be monitored.
research Treatments for Dissecting Cellulitis of the Scalp: A Systematic Review and Treatment Algorithm
More research is needed to find the best treatment for dissecting cellulitis of the scalp.
research Olink proteomics analysis of scalp psoriasis reveals a cytokine storm inflammatory mainly related to bacterial-derived antigens
Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.
research Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
research Ophiasis Alopecia Areata in a Patient With Spondyloarthritis on Secukinumab: A Case Report and Review of the Literature
Secukinumab can cause hair loss, which may improve after stopping the medication.
research IL-33 Contributes to the Pathological Changes of Hair Follicles in Psoriasis: A Potential Target for Psoriatic Alopecia
IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
research VIII International Conference "Interdisciplinary aspects of diseases of the skin and mucous membranes" 11-12th March 2022
Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
research การศึกษาแบบสุ่มแบ่งครึ่งข้างเพื่อเปรียบเทียบประสิทธิภาพการฉีดโบทูลินัมทอกซินชนิดเอกับ 0.9% โซเดียมคลอไรด์ในผื่นสะเก็ดเงินบนศีรษะ
Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.